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patients (33%) had second-line chemotherapy (the majority received 
docetaxel) after progression. The median overall survival was 11.0 
months (95% CI=7.4, 14.6) in those patients who received chemother-
apy after brain radiotherapy. Our results show that only a small fraction 
of NSCLC patients presenting with synchronous brain metastases are 
even considered for chemotherapy after WBRT. Although limited by 
the retrospective nature of the study, good performance status (ECOG 
0-2) NSCLC patients with brain metastases who receive chemotherapy 
after brain radiotherapy have response rates and a median survival 
comparable to the general Stage IV NSCLC population. We propose 
that chemonaive NSCLC patients who receive radiotherapy treatment 
for synchronous brain metastases, and maintain an adequate perfor-
mance status, should be considered for chemotherapy and should not be 
routinely excluded from clinical trials involving systemic therapy.
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Background: The combination of cisplatin and vinorelbine is a refer-
ence regimen in ﬁrst-line therapy for advanced NSCLC. The correla-
tion between predictive genetic markers and clinical endpoints may 
improve the prediction of treatment success and thereby the tailoring 
of chemotherapy. In this trial, predictive genetic markers of response to 
CDDP/VRL were examined in genomic DNA and cDNA derived from 
tumors and circulating tumors. 
Methods: 238 chemonaive p with stage IIIB (pleural effusion or 
supraclavicular lymph nodes)-IV or recurrent NSCLC were accrued at 
35 sites between April 2004 and January 2006. Treatment consisted of 
CDDP 75 mg/m2 IV day 1 plus VRL 25 mg/m2 IV or 60-80 mg/m2 oral, 
days 1, 8 every 21 days. DNA samples were collected from primary 
tumors for the assessment of microtubule associated protein 4 (MAP4) 
and from serum for checkpoint forkhead-associated and ring ﬁnger 
(CHFR) methylation. 
Results: Data on 207 p is available. Median age 62 years (38-80); 
males: 84.5%; smokers: 79.2%; PS 0-1: 94.5%; adenocarcinoma, 
48.4% / squamous, 34.2%; stage IIIB: 16.9%, IV: 83.1%. Median 
cycles: 4 (1-12). Hematological toxicities (%p): grade 3/4 neutropenia, 
8.7%/7.7%; grade 3/4 thrombocytopenia, 0.5%/1.0%; grade 3 anemia, 
2.4%. Febrile neutropenia appeared in 12 p (5,3%). Non-hematologi-
cal toxicities (%p): pulmonary grade 3/4, 3.4%/2.4%; nausea/vomiting 
grade 3/4, 7.7%/0.5%; asthenia grade 3, 12.6%; pain grade 3, 5.8%; 
infection grade 3/4, 3.9%/0.5%; neurotoxicity grade 3, 0.5%. Efﬁcacy 
in evaluable population: CR, 2.8%; PR, 30.7%; ORR, 33.5% (95% 
CI, 26.6% to 40.4%); SD, 36.3%. With a median follow up of 6.6 
months, median survival for the whole population was 8.9 months (m), 
progression free survival 5 m, event free survival 4.8 m, 1-year survival 
39.4%.
Conclusions: The tolerability, efﬁcacy and survival results of this trial 
conﬁrm that CDDP/VRL is effective as ﬁrst-line therapy, presenting a 
favourable toxicity proﬁle in p with advanced NSCLC. Complete data 
on genetic markers will be presented.
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Aim: This Phase II study was conducted in order to deﬁne the efﬁcacy 
and safety of Carboplatin-Pemetrexed combination as a second-line 
treatment for NSCLC patients.
Patient and Methods: Twenty six patients with measurable NSCLC 
and PS 0-1 (ECOG scale) who had failed or relapsed after initial 
chemotherapy, received Carboplatin AUC4 and Pemetrexed 350mg/m2 
on day 1 and 15 on up to 6 q28 cycles. Vitamin B12 and folic acid 
supplementation was given. All patients received GCSF for days 3-5 
and 17-19 of cycles. Response to treatment was evaluated by response 
evaluation criteria in solid tumors (RECIST), and toxicity was graded 
according to the National Cancer Institute Common Toxicity Criteria 
version 3.0.
Results: The most common severs hematological adverse events (CTC 
Grade 3,4) was thrombocytopenia in two patients (7.6%), and anemia 
in one (3.85%). Serious non hematological toxicity was onycholyses 
(3.85%), neuropathy (3.85%), stomatitis (3.85%), and fatigue (3.85%). 
The median number of treatment cycles was 4. Fourteen patients (54%) 
received all six cycles. One patient reported as complete responder 
(3.85%), 5 as partial responders (19%) and 4 had stable disease 
(15.4%), with over all response rate of 38.46%. Median time to pro-
gression for 2nd line chemotherapy and overall survival was 6 and 12.6 
months respectively. 
Conclusions: Second line regimen with carboplatin-pemetrexated in 
intensive schedule is well tolerate and effective treatment for resistant 
or relapsed, after initial chemotherapy, NSCLC.
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Objective: To study the effects of Taxotere, Celecoxib and the combi-
nation of both on proliferation and apoptosis of NSCLC cell. 
Methods: Investigate the effect of Taxotere, Celecoxib and the combi-
nation of both on proliferation of NSCLC A549 by MTT assays. Detect 
the change of apoptosis, cell cycle and the expression of COX-2 protein 
using ﬂow cytometry analysis and immunocytochemistry, respectively. 
